Skip to main content
OBX
NASDAQ Life Sciences

Obsidian 10-Q: $50.7M Q3 Loss, $324.4M Cash Into 2H 2028, New Director

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$12.48
Mkt Cap
$770.926M
52W Low
$9.6
52W High
$49.97
52W Position info
30% above low
Off High info
75% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

OBX sits 30% above its 52-week low of $9.6.

Summary

Obsidian's first post-merger 10-Q shows a $50.7 million Q3 loss (including a $15.1 million Galera IPR&D charge) and $324.4 million in cash and securities, enough to fund operations into the second half of 2028. The filing also adds a new independent director and extended Bedford and Cambridge leases.


Key Events · Earnings and Guidance · OBX

  • Q3 Loss of $50.7M on Galera Charge

    Net loss was $50.7 million, or $1.23 per share, for the three months ended September 30, 2026, including $15.1 million of acquired in-process R&D expense tied to the Galera transaction.

  • Cash of $324.4M Funds Operations Into 2H 2028

    Cash, cash equivalents and marketable securities totaled $324.4 million at September 30, 2026, up from $80.5 million at year-end 2025 after the $350.0 million PIPE, which the company expects to support operations into the second half of 2028.

  • New Independent Director Added

    The board expanded from six to seven directors with the November 10, 2026 appointment of Mark Reisenauer, former Assertio CEO; he received an initial option for 75,364 shares at $13.74.

  • Bedford and Cambridge Leases Extended

    The Bedford lease was extended through May 31, 2031 with 16,091 additional square feet, and the Cambridge lease through May 31, 2027, adding roughly $1.1 million to the operating lease liability and right-of-use asset.


Analysis · OBX · Life Sciences

The 10-Q confirms the quarter the 8-K flagged hours earlier, but it is the first full look at the post-merger balance sheet: $324.4 million in cash and securities against a $50.7 million quarterly loss, with the company guiding that runway into the second half of 2028. A one-time $15.1 million charge for the Galera in-process R&D inflates the loss, so the underlying cash burn is closer to $35 million a quarter. Two new items land here rather than in the 8-K: a seventh board seat filled by commercial oncology executive Mark Reisenauer, and lease amendments that lock in the Bedford expansion through 2031 and the Cambridge space through May 2027.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OBX was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.9M. The 52-week trading range was $9.60 to $49.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OBX - Latest Insights

OBX
Nov 12, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.56 info
Change: +$0.080 (+0.64%) info
Market Cap: $775.867M info
OBX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $12.48
Real-time Price: $12.56 info
Change: +$0.080 (+0.64%) info
Market Cap: $775.867M info
OBX
Aug 14, 2026, 4:29 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $19.00
Real-time Price: $12.56 info
Change: -$6.44 (-34%) info
Market Cap: $775.867M info
OBX
Aug 03, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $26.00
Real-time Price: $12.56 info
Change: -$13.44 (-52%) info
Market Cap: $775.867M info